Oyster Point Pharma Inc logo

OYST - Oyster Point Pharma Inc Share Price

$21 0.2  0.8%

Last Trade - 03/03/21

Sector
Healthcare
Size
Mid Cap
Market Cap £387.0m
Enterprise Value £249.0m
Revenue £n/a
Position in Universe 3388th / 6643
Bullish
Bearish
Unlock OYST Revenue
Momentum
Relative Strength (%)
1m +7.39%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -46.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 12.3 79.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, OysterPoint Pharma Inc revenues was not reported. Net lossincreased 54% to $70.5M. Higher net loss reflects Generaland administrative increase from $11M to $25.2M (expense),Research and development increase of 18% to $38.8M(expense), Stock-based Compensation in SGA increase from$2.7M to $6M (expense). Basic Earnings per Share excludingExtraordinary Items decreased from -$2.14 to -$2.92.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

OYST Revenue Unlock OYST Revenue

Net Income

OYST Net Income Unlock OYST Revenue

Normalised EPS

OYST Normalised EPS Unlock OYST Revenue

PE Ratio Range

OYST PE Ratio Range Unlock OYST Revenue

Dividend Yield Range

OYST Dividend Yield Range Unlock OYST Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OYST EPS Forecasts Unlock OYST Revenue
Profile Summary

Oyster Point Pharma, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate is OC-01 (varenicline), a selective nicotinic acetylcholine receptor (nAChR) agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the TPP and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity, and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated June 30, 2015
Public Since October 31, 2019
No. of Shareholders: 70
No. of Employees: 62
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 25,909,694
Free Float (0.0%)
Eligible for
ISAs
SIPPs
OYST Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for OYST
Upcoming Events for OYST
Frequently Asked Questions for Oyster Point Pharma Inc
What is the Oyster Point Pharma Inc share price?

As of 03/03/21, shares in Oyster Point Pharma Inc are trading at $21, giving the company a market capitalisation of £387.0m. This share price information is delayed by 15 minutes.

How has the Oyster Point Pharma Inc share price performed this year?

Shares in Oyster Point Pharma Inc are currently trading at $21 and the price has moved by -43.03% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oyster Point Pharma Inc price has moved by -56.15% over the past year.

What are the analyst and broker recommendations for Oyster Point Pharma Inc?

There are no analysts currently covering Oyster Point Pharma Inc.

When will Oyster Point Pharma Inc next release its financial results?

Oyster Point Pharma Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Oyster Point Pharma Inc dividend yield?

Oyster Point Pharma Inc does not currently pay a dividend.

Does Oyster Point Pharma Inc pay a dividend?

Oyster Point Pharma Inc does not currently pay a dividend.

When does Oyster Point Pharma Inc next pay dividends?

Oyster Point Pharma Inc does not currently pay a dividend.

How do I buy Oyster Point Pharma Inc shares?

To buy shares in Oyster Point Pharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oyster Point Pharma Inc?

Shares in Oyster Point Pharma Inc are currently trading at $21, giving the company a market capitalisation of £387.0m.

Where are Oyster Point Pharma Inc shares listed? Where are Oyster Point Pharma Inc shares listed?

Here are the trading details for Oyster Point Pharma Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: OYST
What kind of share is Oyster Point Pharma Inc?

Based on an overall assessment of its quality, value and momentum, Oyster Point Pharma Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oyster Point Pharma Inc share price forecast 2021?

Shares in Oyster Point Pharma Inc are currently priced at $21. At that level they are trading at 0.212% discount to the analyst consensus target price of 0.00.

Analysts covering Oyster Point Pharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.733 for the next financial year.

How can I tell whether the Oyster Point Pharma Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oyster Point Pharma Inc. Over the past six months, the relative strength of its shares against the market has been -10.19%. At the current price of $21, shares in Oyster Point Pharma Inc are trading at -10.46% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oyster Point Pharma Inc PE Ratio?

We were not able to find PE ratio data for Oyster Point Pharma Inc.

Who are the key directors of Oyster Point Pharma Inc?

Oyster Point Pharma Inc's management team is headed by:

Jeffrey Nau - PRE
Mark Murray - DRC
Daniel Lochner - CFO
John Snisarenko - OTH
William Link - IND
Clare Ozawa - IND
Ali Behbahani - CHM
Benjamin Tsai - IND
Michael Atieh - DRC
Marian Macsai - OTH
Eric Carlson - CSO
Who are the major shareholders of Oyster Point Pharma Inc?

Here are the top five shareholders of Oyster Point Pharma Inc based on the size of their shareholding:

New Enterprise Associates (NEA) Venture Capital
Percentage owned: 22.87% (5.93m shares)
Versant Ventures Venture Capital
Percentage owned: 20.28% (5.26m shares)
Invus Financial Advisors, LLC Hedge Fund
Percentage owned: 10.69% (2.77m shares)
RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 7.43% (1.93m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 5.8% (1.50m shares)
Similar to OYST
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.